H3 Pharma Plans First Quarter Response To Sanvar IR "Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA letter requests additional supportive efficacy data and further information related to manufacturing. H3 Pharma expects that the results from a recently completed Phase III study will address the issues cited in the letter.